首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   13022篇
  免费   1127篇
  国内免费   7篇
  2021年   163篇
  2020年   88篇
  2019年   146篇
  2018年   131篇
  2017年   117篇
  2016年   262篇
  2015年   451篇
  2014年   499篇
  2013年   693篇
  2012年   820篇
  2011年   839篇
  2010年   532篇
  2009年   509篇
  2008年   725篇
  2007年   733篇
  2006年   640篇
  2005年   703篇
  2004年   678篇
  2003年   615篇
  2002年   608篇
  2001年   115篇
  2000年   96篇
  1999年   121篇
  1998年   171篇
  1997年   112篇
  1996年   87篇
  1995年   91篇
  1994年   92篇
  1993年   89篇
  1992年   96篇
  1991年   86篇
  1990年   82篇
  1989年   70篇
  1988年   75篇
  1987年   84篇
  1986年   85篇
  1985年   81篇
  1984年   123篇
  1983年   99篇
  1982年   123篇
  1981年   130篇
  1980年   145篇
  1979年   112篇
  1978年   103篇
  1977年   107篇
  1976年   87篇
  1975年   88篇
  1974年   94篇
  1973年   76篇
  1969年   65篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Based on its proven anabolic effects on bone in osteoporosis patients, recombinant parathyroid hormone (PTH1-34) has been evaluated as a potential therapy for skeletal repair. In animals, the effect of PTH1-34 has been investigated in various skeletal repair models such as fractures, allografting, spinal arthrodesis and distraction osteogenesis. These studies have demonstrated that intermittent PTH1-34 treatment enhances and accelerates the skeletal repair process via a number of mechanisms, which include effects on mesenchymal stem cells, angiogenesis, chondrogenesis, bone formation and resorption. Furthermore, PTH1-34 has been shown to enhance bone repair in challenged animal models of aging, inflammatory arthritis and glucocorticoid-induced bone loss. This pre-clinical success has led to off-label clinical use and a number of case reports documenting PTH1-34 treatment of delayed-unions and non-unions have been published. Although a recently completed phase 2 clinical trial of PTH1-34 treatment of patients with radius fracture has failed to achieve its primary outcome, largely because of effective healing in the placebo group, several secondary outcomes are statistically significant, highlighting important issues concerning the appropriate patient population for PTH1-34 therapy in skeletal repair. Here, we review our current knowledge of the effects of PTH1-34 therapy for bone healing, enumerate several critical unresolved issues (e.g., appropriate dosing regimen and indications) and discuss the long-term potential of this drug as an adjuvant for endogenous tissue engineering.  相似文献   
2.
3.
4.
5.
6.
7.
8.
In the American lobster (Homarus americanus) the biogenic amines serotonin and octopamine appear to play important and opposite roles in the regulation of aggressive behavior, in the establishment and/or maintenance of dominant and subordinate behavioral states and in the modulation of the associated postural stances and escape responses. The octopamine-containing neurosecretory neurons in the thoracic regions of the lobster ventral nerve cord fall into two morphological subgroups, the root octopamine cells, a classical neurohemal group with release regions along second thoracic roots, and the claw octopamine cells, a group that selectively innervates the claws. Cells of both subgroups have additional sets of endings within neuropil regions of ganglia of the ventral nerve cord. Octopamine neurosecretory neurons generally are silent, but when spontaneously active or when activated, they show large overshooting action potentials with prominent after-hyperpolarizations. Autoinhibition after high-frequency firing, which is also seen in other crustacean neurosecretory cells, is readily apparent in these cells. The cells show no spontaneous synaptic activity, but appear to be excited by a unitary source. Stimulation of lateral or medial giant axons, which excite serotonergic cells yielded no response in octopaminergic neurosecretory cells and no evidence for direct interactions between pairs of octopamine neurons, or between the octopaminergic and the serotonergic sets of neurosecretory neurons was found.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号